Previous 10 | Next 10 |
Invitae to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire SAN FRANCISCO , Jan. 4, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight , president & chief executive office...
Summary Sema4's restructuring plan has a number of potential downsides that could affect the company's cash position in the coming few quarters. The booting of the CEO signals the start of a strategic focus on short-term survival away from long-term growth. Even if management succee...
Invitae Completes Selected Assets Sale of its Next Generation Sequencing (NGS) research assays to Integrated DNA Technologies, Inc. PR Newswire — Invitae will continue to invest in its precision oncology focused lab developed test (LDT) offerings — —...
Down nearly 85% in 2022. That's the situation for Invitae (NYSE: NVTA) stock. There's no way to spin that as positive news. However, this steep sell-off is also water under the bridge. Could Invitae be a good pick to buy going forward? Opinions vary. Here are the bull and bear argumen...
Vertex Pharmaceuticals (NASDAQ: VRTX) and Invitae (NYSE: NVTA) have gone in different directions this year when it comes to share price, with Vertex's stock up more than 43% so far and Invitae's shares plunging over 84%. Looking at these two biotech stocks from a long-term p...
Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research PR Newswire – Invitae to report on secondary patient data use, demonstrating real-world impact of de-identified patient data on the advancement of precision medicin...
Invitae Launches Rare Patient Network for Pediatric Patients With Rare Neurodevelopmental Diseases PR Newswire – Ciitizen real-world data platform expansion helps advance research and potentially improve outcomes for patients with pediatric epilepsy and/or developmental d...
Invitae (NYSE: NVTA) is a genetic testing company that's in its early growth stages, so shareholders should expect to take on some risk with a stock like this. But in Invitae's case, the company is burning through an excessive amount of money, and the risk could be too significant f...
Shares of medical genetics testing company Invitae (NYSE: NVTA) rose 11% on Tuesday. The stock is still down more than 76% so far this year. Invitate didn't have any announcements on Tuesday, though it is presenting research this week in Nashville, Tennessee, at the National Soc...
Summary Invitae Corporation has one chance to leverage itself into profitability in the next 12 - 18 months. The cash balance is barely enough to cover the company's cash burn, even if it achieves its 2023, leaving little room for error. Executing the "realignment plan" must b...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...